Breakfast News: Summit’s FDA Setback Isn’t the End
SMMT shares plunged more than 20% after the FDA issued a Complete Response Letter for ivonescimab, Summit Therapeutics' cancer drug. The agency cited a failure to meet overall survival statistical requirements in the HARMONi trial.
The rejection is narrower than the price action suggests. Analysts view the setback as limited because it applies only to second-line treatment. The drug's blockbuster potential, per those analysts, sits in first-line settings, which this decision does not touch.
Summit's runway looks intact. The company reports $630 million in cash reserves and 17 ongoing late-stage trials. AZN provides strong financial backing, a notable support factor for a developer absorbing a regulatory rejection.
Interpretation: a 20%-plus drop on a second-line setback implies the market priced in a cleaner approval path than the HARMONi data delivered. If analysts are right that first-line trials drive the valuation, the selloff may overstate the damage, though the survival miss raises the bar for those later readouts.
NVDA appears in the classifier context for this story, but the source provides no direct link between it and the FDA decision, so no read-through is drawn here.